EC approves Shire's Vpriv

The European Commission approved an MAA from Shire plc (LSE:SHP; NASDAQ:SHPGY) for Vpriv velaglucerase alfa to treat Type I Gaucher's disease. FDA approved the glucocerebrosidase enzyme replacement th...